skip to Main Content

Opicapone Treatment Initiation Open-Label Study


Brief Summary:

This is an observational study to describe the treatment patterns and clinical outcomes
observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson’s
disease patients experiencing “off” episodes with motor fluctuations


Inclusion Criteria:

– Must be able to complete electronic patient-reported outcome instruments

– Parkinson’s disease patients experiencing “off” episodes

– Patient receiving concomitant levodopa/carbidopa, and as deemed appropriate by the
physician, newly initiating ONGENTYS as adjunctive treatment

Exclusion Criteria:

– Patient is not cognitively able to complete the study requirements

– Patient is not able to complete the study duration of 6 months

– History of moderate or severe hepatic impairment

– Patient has end-stage renal disease

– Concomitant use of non-selective monoamine oxidase (MAO) inhibitor or
catechol-O-methyltransferase (COMT) inhibitors (patients entering study may switch
from other COMT inhibitors to ONGENTYS)

– History of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasms

– Currently enrolled in an interventional clinical trial

– Currently or previously received ONGENTYS


  • Neurocrine clinical site, Los Gatos, California, United States, 95032
Back To Top